Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro-oncology (Charlottesville, Va.) Va.), 2022-10, Vol.24 (10), p.1776-1789
Hauptverfasser: Desai, Ami V, Robinson, Giles W, Gauvain, Karen, Basu, Ellen M, Macy, Margaret E, Maese, Luke, Whipple, Nicholas S, Sabnis, Amit J, Foster, Jennifer H, Shusterman, Suzanne, Yoon, Janet, Weiss, Brian D, Abdelbaki, Mohamed S, Armstrong, Amy E, Cash, Thomas, Pratilas, Christine A, Corradini, Nadège, Marshall, Lynley V, Farid-Kapadia, Mufiza, Chohan, Saibah, Devlin, Clare, Meneses-Lorente, Georgina, Cardenas, Alison, Hutchinson, Katherine E, Bergthold, Guillaume, Caron, Hubert, Chow Maneval, Edna, Gajjar, Amar, Fox, Elizabeth
Format: Artikel
Sprache:eng
Schlagworte:
Benzamides
Carcinoma, Non-Small-Cell Lung
Child
Humans
Indazoles - pharmacology
Indazoles - therapeutic use
Lung Neoplasms - pathology
Pediatric Neuro-Oncology
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Receptor Protein-Tyrosine Kinases
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investigating the recommended phase 2 dose (RP2D) and activity of entrectinib in pediatric patients with solid tumors including primary central nervous system tumors. Methods STARTRK-NG (NCT02650401) is a phase 1/2 trial. Phase 1, dose-escalation of oral, once-daily entrectinib, enrolled patients aged
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/noac087